Patient-reported outcomes, health-related quality of life, and clinical outcomes for urothelial cancer patients receiving chemo-or immunotherapy: A real-life experience

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Patient-reported outcomes, health-related quality of life, and clinical outcomes for urothelial cancer patients receiving chemo-or immunotherapy : A real-life experience. / Taarnhøj, Gry Assam; Lindberg, Henriette; Johansen, Christoffer; Pappot, Helle.

In: Journal of Clinical Medicine, Vol. 10, No. 9, 1852, 2021.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Taarnhøj, GA, Lindberg, H, Johansen, C & Pappot, H 2021, 'Patient-reported outcomes, health-related quality of life, and clinical outcomes for urothelial cancer patients receiving chemo-or immunotherapy: A real-life experience', Journal of Clinical Medicine, vol. 10, no. 9, 1852. https://doi.org/10.3390/jcm10091852

APA

Taarnhøj, G. A., Lindberg, H., Johansen, C., & Pappot, H. (2021). Patient-reported outcomes, health-related quality of life, and clinical outcomes for urothelial cancer patients receiving chemo-or immunotherapy: A real-life experience. Journal of Clinical Medicine, 10(9), [1852]. https://doi.org/10.3390/jcm10091852

Vancouver

Taarnhøj GA, Lindberg H, Johansen C, Pappot H. Patient-reported outcomes, health-related quality of life, and clinical outcomes for urothelial cancer patients receiving chemo-or immunotherapy: A real-life experience. Journal of Clinical Medicine. 2021;10(9). 1852. https://doi.org/10.3390/jcm10091852

Author

Taarnhøj, Gry Assam ; Lindberg, Henriette ; Johansen, Christoffer ; Pappot, Helle. / Patient-reported outcomes, health-related quality of life, and clinical outcomes for urothelial cancer patients receiving chemo-or immunotherapy : A real-life experience. In: Journal of Clinical Medicine. 2021 ; Vol. 10, No. 9.

Bibtex

@article{7a1fddc01aa14eb28526e15e870052b0,
title = "Patient-reported outcomes, health-related quality of life, and clinical outcomes for urothelial cancer patients receiving chemo-or immunotherapy: A real-life experience",
abstract = "Patients with urothelial cell carcinoma (UCC) often have comorbidities, which cause trouble for the completion of oncological treatment, and little is known about their quality of life (QoL). The aim of the present study was to obtain and describe patient-reported outcomes (PRO) and QoL data from UCC patients in the treatment for locally advanced muscle-invasive or metastatic UCC. A total of 79 patients with UCC completed four questionnaires (EORTC QLQ-C30, QLQ-BLM30, HADS, and select PRO-CTCAE{\texttrademark} questions) once weekly during their treatment. From those, 26 patients (33%) underwent neoadjuvant treatment for local disease while 53 patients (67%) were treated for metastatic disease. Of all patients, 54% did not complete the planned treatment due to progression, nephrotoxicity, death, or intolerable symptoms during treatment. The five most prevalent PRO-CTCAE grade ≥ 2 symptoms were frequent urination (37%), fatigue (35%), pain (31%), dry mouth (23%), and swelling of the arms or legs (23%). The baseline mean overall QoL was 61 (±SD 24) for all patients (neoadjuvant (73, ±SD 19) and metastatic (54, ±SD 24)) and remained stable over the course of treatment for both groups. A stable overall QoL was observed for the patients in this study. More than half of the patients did not, however, complete the planned treatment. Further supportive care is warranted for bladder cancer patients.",
keywords = "Bladder cancer, Chemotherapy, Immunotherapy, Patient-reported outcomes, Quality of life, Side effects, Urothelial cell carcinoma",
author = "Taarnh{\o}j, {Gry Assam} and Henriette Lindberg and Christoffer Johansen and Helle Pappot",
note = "Funding Information: One of the authors (SK) is thankful to SERB-DST, Govt of India for the award of Young Scientist under Start-up Research Grant. The authors are also thankful to Dr. S M Venkatapathi, Chairman, East Point Group of Institutions for providing infrastructural facilities and to Dr. B M Satish, Principal, East Point College of Engineering and Technology for his support and encouragement. Publisher Copyright: {\textcopyright} 2021 by the authors. Licensee MDPI, Basel, Switzerland.",
year = "2021",
doi = "10.3390/jcm10091852",
language = "English",
volume = "10",
journal = "Journal of Clinical Medicine",
issn = "2077-0383",
publisher = "M D P I AG",
number = "9",

}

RIS

TY - JOUR

T1 - Patient-reported outcomes, health-related quality of life, and clinical outcomes for urothelial cancer patients receiving chemo-or immunotherapy

T2 - A real-life experience

AU - Taarnhøj, Gry Assam

AU - Lindberg, Henriette

AU - Johansen, Christoffer

AU - Pappot, Helle

N1 - Funding Information: One of the authors (SK) is thankful to SERB-DST, Govt of India for the award of Young Scientist under Start-up Research Grant. The authors are also thankful to Dr. S M Venkatapathi, Chairman, East Point Group of Institutions for providing infrastructural facilities and to Dr. B M Satish, Principal, East Point College of Engineering and Technology for his support and encouragement. Publisher Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland.

PY - 2021

Y1 - 2021

N2 - Patients with urothelial cell carcinoma (UCC) often have comorbidities, which cause trouble for the completion of oncological treatment, and little is known about their quality of life (QoL). The aim of the present study was to obtain and describe patient-reported outcomes (PRO) and QoL data from UCC patients in the treatment for locally advanced muscle-invasive or metastatic UCC. A total of 79 patients with UCC completed four questionnaires (EORTC QLQ-C30, QLQ-BLM30, HADS, and select PRO-CTCAE™ questions) once weekly during their treatment. From those, 26 patients (33%) underwent neoadjuvant treatment for local disease while 53 patients (67%) were treated for metastatic disease. Of all patients, 54% did not complete the planned treatment due to progression, nephrotoxicity, death, or intolerable symptoms during treatment. The five most prevalent PRO-CTCAE grade ≥ 2 symptoms were frequent urination (37%), fatigue (35%), pain (31%), dry mouth (23%), and swelling of the arms or legs (23%). The baseline mean overall QoL was 61 (±SD 24) for all patients (neoadjuvant (73, ±SD 19) and metastatic (54, ±SD 24)) and remained stable over the course of treatment for both groups. A stable overall QoL was observed for the patients in this study. More than half of the patients did not, however, complete the planned treatment. Further supportive care is warranted for bladder cancer patients.

AB - Patients with urothelial cell carcinoma (UCC) often have comorbidities, which cause trouble for the completion of oncological treatment, and little is known about their quality of life (QoL). The aim of the present study was to obtain and describe patient-reported outcomes (PRO) and QoL data from UCC patients in the treatment for locally advanced muscle-invasive or metastatic UCC. A total of 79 patients with UCC completed four questionnaires (EORTC QLQ-C30, QLQ-BLM30, HADS, and select PRO-CTCAE™ questions) once weekly during their treatment. From those, 26 patients (33%) underwent neoadjuvant treatment for local disease while 53 patients (67%) were treated for metastatic disease. Of all patients, 54% did not complete the planned treatment due to progression, nephrotoxicity, death, or intolerable symptoms during treatment. The five most prevalent PRO-CTCAE grade ≥ 2 symptoms were frequent urination (37%), fatigue (35%), pain (31%), dry mouth (23%), and swelling of the arms or legs (23%). The baseline mean overall QoL was 61 (±SD 24) for all patients (neoadjuvant (73, ±SD 19) and metastatic (54, ±SD 24)) and remained stable over the course of treatment for both groups. A stable overall QoL was observed for the patients in this study. More than half of the patients did not, however, complete the planned treatment. Further supportive care is warranted for bladder cancer patients.

KW - Bladder cancer

KW - Chemotherapy

KW - Immunotherapy

KW - Patient-reported outcomes

KW - Quality of life

KW - Side effects

KW - Urothelial cell carcinoma

U2 - 10.3390/jcm10091852

DO - 10.3390/jcm10091852

M3 - Journal article

C2 - 33923176

AN - SCOPUS:85112868674

VL - 10

JO - Journal of Clinical Medicine

JF - Journal of Clinical Medicine

SN - 2077-0383

IS - 9

M1 - 1852

ER -

ID: 301457864